End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.8 CNY | +0.20% | -1.14% | -37.05% |
26/04 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
25/04 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
ETFs positioned on Walvax Biotechnology Co., Ltd.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 15 M€ | +16.75% | ||
0.00% | 8 M€ | +0.60% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.05% | 3.27B | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-13.65% | 32.81B | |
+52.41% | 25B | |
-17.33% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- 300142 Stock
- Funds and ETFs Walvax Biotechnology Co., Ltd.